机译:通过BRCA1 / 2突变和高级浆液卵巢,输卵管或原发性腹膜癌,对PARP抑制剂ABT-767进行PARP抑制剂ABT-767的研究
Erasmus Univ Med Ctr Erasmus MC Canc Inst Rotterdam Netherlands;
Univ Groningen Univ Med Ctr Groningen Groningen Netherlands;
Erasmus Univ Med Ctr Erasmus MC Canc Inst Rotterdam Netherlands;
Radboud Univ Nijmegen Med Ctr Nijmegen Netherlands;
Univ Groningen Univ Med Ctr Groningen Groningen Netherlands;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
AbbVie BV Hoofddorp Hoofddorp Netherlands;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
Myriad Genet Inc Salt Lake City UT USA;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
AbbVie Inc N Chicago IL USA;
Radboud Univ Nijmegen Med Ctr Nijmegen Netherlands;
PARP inhibitor; BRCA; Solid tumor; Ovarian cancer; Homologous recombination deficiency;
机译:通过BRCA1 / 2突变和高级浆液卵巢,输卵管或原发性腹膜癌,对PARP抑制剂ABT-767进行PARP抑制剂ABT-767的研究
机译:BRCA1或BRCA2相关晚期卵巢上皮癌,输卵管癌或原发性腹膜癌患者Iniparib的2期单臂研究
机译:BRCA1或BRCA2相关晚期卵巢上皮癌,输卵管癌或原发性腹膜癌患者Iniparib的2期单臂研究
机译:从自我癌症中确定基因Krca1 / 2中的突变吗?
机译:PARP抑制剂ABT-767在具有BRCA1 / 2突变和高度浆液性卵巢癌输卵管癌或原发性腹膜癌的晚期实体瘤中的1期研究
机译:我对卵巢和输卵管癌症的剂量升级的患者患有高剂量分级的全腹部放射治疗(LDFWAR)的肝脏分级整个腹部放射治疗(LDFWAR)与低剂量分级的全腹部放射治疗(LDFWAR)的最终报告